Prodromal Alpha-Synuclein Screening in Parkinson's Disease Study
Last updated on July 2021Recruitment
- Recruitment Status
- Not yet recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Parkinson Disease
- Type
- Observational
- Design
- Observational Model: CohortTime Perspective: Prospective
Participation Requirements
- Age
- Between 50 years and 99 years
- Gender
- Both males and females
Description
The PASS-PP Study is designed to combine the latest developments in clinical and biomarker research to understand the distribution of risk profiles for PD in the general population, especially regarding non-motor symptoms identify subjects with a likelihood of developing PD follow individuals with a...
The PASS-PP Study is designed to combine the latest developments in clinical and biomarker research to understand the distribution of risk profiles for PD in the general population, especially regarding non-motor symptoms identify subjects with a likelihood of developing PD follow individuals with a high likelihood/risk to develop PD in the future (compared to individuals with low risk and) in a prospective study understand the potential of biological markers to increase prediction of progression/conversion identify subtypes of PD patients, by providing a detailed clinical phenotyping with a main focus on non-motor symptoms cluster provide a framework of ethical handling of early risk disclosure in PD
Tracking Information
- NCT #
- NCT04724941
- Collaborators
- UCB Biopharma SRL
- University of Kiel
- Investigators
- Principal Investigator: Daniela Berg, Prof.Dr. Department for Neurology, University of Kiel
Get Well Soon